Product description
Semaglutide is a modified GLP-1 analog with 94% sequence homology to human GLP-1. Its defined peptide backbone includes substitutions that support DPP-4 stability and attachment of a C18 fatty di-acid, making it useful for laboratory comparison of GLP-1 receptor activation, incretin signaling, and pathway duration.
The specification record provides the identity, supplied format, available quantities, and storage information needed for procurement review and sample tracking. Researchers are responsible for establishing preparation, concentration, controls, and stability procedures appropriate to their validated methods.
